Vaccine deployment characteristics and vaccine uptake

Last registered on December 14, 2020

Pre-Trial

Trial Information

General Information

Title
Vaccine deployment characteristics and vaccine uptake
RCT ID
AEARCTR-0006884
Initial registration date
December 11, 2020

Initial registration date is when the trial was registered.

It corresponds to when the registration was submitted to the Registry to be reviewed for publication.

First published
December 14, 2020, 10:32 AM EST

First published corresponds to when the trial was first made public on the Registry after being reviewed.

Locations

Primary Investigator

Affiliation
University of Wyoming

Other Primary Investigator(s)

PI Affiliation
University of Wyoming
PI Affiliation
University of Wyoming
PI Affiliation
University of Wyoming
PI Affiliation
University of Wyoming

Additional Trial Information

Status
In development
Start date
2020-12-11
End date
2021-01-01
Secondary IDs
Abstract
Growing vaccine hesitancy is a well-documented trend, which may affect the uptake of COVID-19 vaccine. This study aims to determine vaccine uptake across a range of characteristics of the virus and the vaccine. We will conduct a survey in which we vary the value of key parameters, such as (i) the duration of clinical development, (ii) the risk of side effects, (iii) the prevalence of the virus, the vaccine uptake rate once available, and (iv) the reported effectiveness of the vaccine in protecting people from becoming infected. We will determine the proportion of the population that would be willing to take the COVID-19 vaccine right away and 6 months after the vaccine has been available. We will also include an information treatment that informs participants of the rigor of the vaccine trials.
External Link(s)

Registration Citation

Citation
Ashworth, Madison et al. 2020. "Vaccine deployment characteristics and vaccine uptake." AEA RCT Registry. December 14. https://doi.org/10.1257/rct.6884
Experimental Details

Interventions

Intervention(s)
We will conduct a survey in which we vary the value of key parameters, such as (i) the duration of clinical development, (ii) the risk of side effects, (iii) the prevalence of the virus, the vaccine uptake rate once available, and (iv) the reported effectiveness of the vaccine in protecting people from becoming infected. We will determine the proportion of the population that would be willing to take the COVID-19 vaccine right away and 6 months after the vaccine has been available. We will also include an information treatment that informs participants of the rigor of the vaccine trials.
Intervention Start Date
2020-12-11
Intervention End Date
2021-01-01

Primary Outcomes

Primary Outcomes (end points)
The proportion of the population that would be willing to take the COVID-19 vaccine right away and 6 months after the vaccine has been available.
Primary Outcomes (explanation)

Secondary Outcomes

Secondary Outcomes (end points)
Secondary Outcomes (explanation)

Experimental Design

Experimental Design
Participants will be randomized into 1 of 32 treatments which varies vaccine characteristics (side effect rate, effectiveness, and duration of the clinical trial), the number of individuals infected with COVID-19 at the time, and level of information given regarding the vaccine approval process. Participants would be asked about their willingness to take a COVID-19 vaccine under the conditions described in the treatment. If they state they would not take the vaccine they are randomized into 1 of 16 follow up treatments where they will be asked if they would take the vaccine 6 months later given revised side effect rates, vaccine effectiveness, and number previously infected with COVID-19. The percent of the U.S. population that has taken the vaccine in the 6 months will also be varied.
Participants will be asked about the risk factors for contracting the virus, their response to a positive COVID-19 test, and their trust in different information sources.
Experimental Design Details
Participants will be randomized into 1 of 32 treatments which varies vaccine characteristics (side effect rate, effectiveness, and duration of the clinical trial), the number of individuals infected with COVID-19 at the time, and level of information given regarding the vaccine approval process. Participants would be asked about their willingness to take a COVID-19 vaccine under the conditions described in the treatment. If they state they would not take the vaccine they are randomized into 1 of 16 follow up treatments where they will be asked if they would take the vaccine 6 months later given revised side effect rates, vaccine effectiveness, and number previously infected with COVID-19. The percent of the U.S. population that has taken the vaccine in the 6 months will also be varied.
Participants will be asked about the risk factors for contracting the virus, their response to a positive COVID-19 test, and their trust in different information sources.
Randomization Method
Randomization done by computer.
Randomization Unit
Individual
Was the treatment clustered?
No

Experiment Characteristics

Sample size: planned number of clusters
0
Sample size: planned number of observations
3000
Sample size (or number of clusters) by treatment arms
93 per initial treatment and maximum of 5 in follow-up treatments.
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
IRB

Institutional Review Boards (IRBs)

IRB Name
University of Wyoming Institutional Review Board
IRB Approval Date
2020-12-07
IRB Approval Number
N/A

Post-Trial

Post Trial Information

Study Withdrawal

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information

Intervention

Is the intervention completed?
No
Data Collection Complete
Data Publication

Data Publication

Is public data available?
No

Program Files

Program Files
Reports, Papers & Other Materials

Relevant Paper(s)

Reports & Other Materials